<DOC>
	<DOC>NCT01539291</DOC>
	<brief_summary>This study (GS-US-312-0117) is a multicenter, 2-arm, double-blind, parallel-group extension study that is a companion study to Study GS-US-312-0116, to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control.</brief_summary>
	<brief_title>Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Inclusion: Subjects in the primary Phase 3 study (Study GSUS3120116) who are compliant Tolerating primary study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CLL</keyword>
	<keyword>CAL-101</keyword>
	<keyword>CAL 101</keyword>
	<keyword>GS-1101</keyword>
	<keyword>GS 1101</keyword>
	<keyword>PI3K</keyword>
	<keyword>Leukemia</keyword>
	<keyword>GS-US-312-0116</keyword>
	<keyword>idelalisib</keyword>
</DOC>